Avalo Therapeutics Inc (AVTX)
13.00
+0.41
(+3.26%)
USD |
NASDAQ |
Jul 08, 16:00
13.00
0.00 (0.00%)
After-Hours: 19:56
Avalo Therapeutics SG&A Expense (Annual): 10.30M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.30M |
| December 31, 2022 | 20.71M |
| December 31, 2021 | 24.66M |
| December 31, 2020 | 19.76M |
| December 31, 2019 | 11.61M |
| December 31, 2018 | 11.06M |
| Date | Value |
|---|---|
| December 31, 2017 | 8.511M |
| December 31, 2016 | 7.083M |
| December 31, 2015 | 4.423M |
| December 31, 2014 | 4.875M |
| December 31, 2013 | 4.020M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
10.30M
Minimum
2023
24.66M
Maximum
2021
17.41M
Average
19.76M
Median
2020
SG&A Expense (Annual) Benchmarks
| Petros Pharmaceuticals Inc | 9.262M |
| Imunon Inc | 9.743M |
| iBio Inc | 19.02M |
| Ocugen Inc | 31.99M |
| Spectral AI Inc | 20.86M |